Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: A case-based approach

Edith A. Nutescu, Ann K. Wittkowsky, Paul P. Dobesh, David W. Hawkins, William E. Dager

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

OBJECTIVE: To review the risk of venous thromboembolism (VTE) in various patient populations and evaluate the agents available for the prevention and treatment of VTE using a case-based approach. DATA SOURCES: A MEDLINE search (1995-July 2006) was conducted to identify relevant literature. Additional references were reviewed from selected articles. STUDY SELECTION AND DATA EXTRACTION: Articles related to the prevention of VTE in orthopedic surgery, general surgery, and medically ill patients, as well as the treatment of VTE, were reviewed. DATA SYNTHESIS: Pharmacologic options for the prevention and treatment of VTE include warfarin, unfractionated heparin (UFH), low-molecular-weight heparins (LMWH), and fondaparinux. Current guidelines support the use of warfarin, LMWH, or fondaparinux for VTE prophylaxis following lower limb major orthopedic surgery. For VTE prophylaxis in hospitalized medical patients or patients undergoing general surgery, use of UFH and LMWH is supported; however, recent data on fondaparinux suggest that it is also effective in these patient populations. The use of UFH or LMWH (both in conjunction with warfarin) for treatment of acute deep venous thrombosis or nonmassive pulmonary embolism is recommended. Recent data suggest that fondaparinux (in conjunction with warfarin) is also effective for the treatment of VTE. A variety of pharmacokinetic, pharmacodynamic, and pharmacoeconomic factors differentiate each agent for the various indications. CONCLUSIONS: Currently, a "one-size-fits-all" anticoagulant is not available for treatment of VTE. A variety of patient factors, including type of surgery, medical indication, thrombotic risk factors, bleeding risk, history of heparin-induced thrombocytopenia, and a variety of comorbid conditions can affect the safety, efficacy, and selection of appropriate VTE therapy.

Original languageEnglish (US)
Pages (from-to)1558-1571
Number of pages14
JournalAnnals of Pharmacotherapy
Volume40
Issue number9
DOIs
StatePublished - Sep 1 2006

Fingerprint

Fibrinolytic Agents
Venous Thromboembolism
Low Molecular Weight Heparin
Warfarin
Heparin
Therapeutics
Orthopedics
Pharmaceutical Economics
Pulmonary Embolism
MEDLINE
Venous Thrombosis
Thrombocytopenia
Anticoagulants
Population
Lower Extremity
Pharmacokinetics
Guidelines
Hemorrhage
Safety

Keywords

  • Anticoagulants
  • Direct thrombin inhibitors
  • Factor-xa inhibitors
  • Heparin
  • Low-molecular-weight heparin
  • Venous thromboembolism
  • Warfarin

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE : A case-based approach. / Nutescu, Edith A.; Wittkowsky, Ann K.; Dobesh, Paul P.; Hawkins, David W.; Dager, William E.

In: Annals of Pharmacotherapy, Vol. 40, No. 9, 01.09.2006, p. 1558-1571.

Research output: Contribution to journalArticle

Nutescu, Edith A. ; Wittkowsky, Ann K. ; Dobesh, Paul P. ; Hawkins, David W. ; Dager, William E. / Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE : A case-based approach. In: Annals of Pharmacotherapy. 2006 ; Vol. 40, No. 9. pp. 1558-1571.
@article{7c43582fa5e94807b893f0605f01c4a0,
title = "Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: A case-based approach",
abstract = "OBJECTIVE: To review the risk of venous thromboembolism (VTE) in various patient populations and evaluate the agents available for the prevention and treatment of VTE using a case-based approach. DATA SOURCES: A MEDLINE search (1995-July 2006) was conducted to identify relevant literature. Additional references were reviewed from selected articles. STUDY SELECTION AND DATA EXTRACTION: Articles related to the prevention of VTE in orthopedic surgery, general surgery, and medically ill patients, as well as the treatment of VTE, were reviewed. DATA SYNTHESIS: Pharmacologic options for the prevention and treatment of VTE include warfarin, unfractionated heparin (UFH), low-molecular-weight heparins (LMWH), and fondaparinux. Current guidelines support the use of warfarin, LMWH, or fondaparinux for VTE prophylaxis following lower limb major orthopedic surgery. For VTE prophylaxis in hospitalized medical patients or patients undergoing general surgery, use of UFH and LMWH is supported; however, recent data on fondaparinux suggest that it is also effective in these patient populations. The use of UFH or LMWH (both in conjunction with warfarin) for treatment of acute deep venous thrombosis or nonmassive pulmonary embolism is recommended. Recent data suggest that fondaparinux (in conjunction with warfarin) is also effective for the treatment of VTE. A variety of pharmacokinetic, pharmacodynamic, and pharmacoeconomic factors differentiate each agent for the various indications. CONCLUSIONS: Currently, a {"}one-size-fits-all{"} anticoagulant is not available for treatment of VTE. A variety of patient factors, including type of surgery, medical indication, thrombotic risk factors, bleeding risk, history of heparin-induced thrombocytopenia, and a variety of comorbid conditions can affect the safety, efficacy, and selection of appropriate VTE therapy.",
keywords = "Anticoagulants, Direct thrombin inhibitors, Factor-xa inhibitors, Heparin, Low-molecular-weight heparin, Venous thromboembolism, Warfarin",
author = "Nutescu, {Edith A.} and Wittkowsky, {Ann K.} and Dobesh, {Paul P.} and Hawkins, {David W.} and Dager, {William E.}",
year = "2006",
month = "9",
day = "1",
doi = "10.1345/aph.1G577",
language = "English (US)",
volume = "40",
pages = "1558--1571",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "9",

}

TY - JOUR

T1 - Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE

T2 - A case-based approach

AU - Nutescu, Edith A.

AU - Wittkowsky, Ann K.

AU - Dobesh, Paul P.

AU - Hawkins, David W.

AU - Dager, William E.

PY - 2006/9/1

Y1 - 2006/9/1

N2 - OBJECTIVE: To review the risk of venous thromboembolism (VTE) in various patient populations and evaluate the agents available for the prevention and treatment of VTE using a case-based approach. DATA SOURCES: A MEDLINE search (1995-July 2006) was conducted to identify relevant literature. Additional references were reviewed from selected articles. STUDY SELECTION AND DATA EXTRACTION: Articles related to the prevention of VTE in orthopedic surgery, general surgery, and medically ill patients, as well as the treatment of VTE, were reviewed. DATA SYNTHESIS: Pharmacologic options for the prevention and treatment of VTE include warfarin, unfractionated heparin (UFH), low-molecular-weight heparins (LMWH), and fondaparinux. Current guidelines support the use of warfarin, LMWH, or fondaparinux for VTE prophylaxis following lower limb major orthopedic surgery. For VTE prophylaxis in hospitalized medical patients or patients undergoing general surgery, use of UFH and LMWH is supported; however, recent data on fondaparinux suggest that it is also effective in these patient populations. The use of UFH or LMWH (both in conjunction with warfarin) for treatment of acute deep venous thrombosis or nonmassive pulmonary embolism is recommended. Recent data suggest that fondaparinux (in conjunction with warfarin) is also effective for the treatment of VTE. A variety of pharmacokinetic, pharmacodynamic, and pharmacoeconomic factors differentiate each agent for the various indications. CONCLUSIONS: Currently, a "one-size-fits-all" anticoagulant is not available for treatment of VTE. A variety of patient factors, including type of surgery, medical indication, thrombotic risk factors, bleeding risk, history of heparin-induced thrombocytopenia, and a variety of comorbid conditions can affect the safety, efficacy, and selection of appropriate VTE therapy.

AB - OBJECTIVE: To review the risk of venous thromboembolism (VTE) in various patient populations and evaluate the agents available for the prevention and treatment of VTE using a case-based approach. DATA SOURCES: A MEDLINE search (1995-July 2006) was conducted to identify relevant literature. Additional references were reviewed from selected articles. STUDY SELECTION AND DATA EXTRACTION: Articles related to the prevention of VTE in orthopedic surgery, general surgery, and medically ill patients, as well as the treatment of VTE, were reviewed. DATA SYNTHESIS: Pharmacologic options for the prevention and treatment of VTE include warfarin, unfractionated heparin (UFH), low-molecular-weight heparins (LMWH), and fondaparinux. Current guidelines support the use of warfarin, LMWH, or fondaparinux for VTE prophylaxis following lower limb major orthopedic surgery. For VTE prophylaxis in hospitalized medical patients or patients undergoing general surgery, use of UFH and LMWH is supported; however, recent data on fondaparinux suggest that it is also effective in these patient populations. The use of UFH or LMWH (both in conjunction with warfarin) for treatment of acute deep venous thrombosis or nonmassive pulmonary embolism is recommended. Recent data suggest that fondaparinux (in conjunction with warfarin) is also effective for the treatment of VTE. A variety of pharmacokinetic, pharmacodynamic, and pharmacoeconomic factors differentiate each agent for the various indications. CONCLUSIONS: Currently, a "one-size-fits-all" anticoagulant is not available for treatment of VTE. A variety of patient factors, including type of surgery, medical indication, thrombotic risk factors, bleeding risk, history of heparin-induced thrombocytopenia, and a variety of comorbid conditions can affect the safety, efficacy, and selection of appropriate VTE therapy.

KW - Anticoagulants

KW - Direct thrombin inhibitors

KW - Factor-xa inhibitors

KW - Heparin

KW - Low-molecular-weight heparin

KW - Venous thromboembolism

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=33748304287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748304287&partnerID=8YFLogxK

U2 - 10.1345/aph.1G577

DO - 10.1345/aph.1G577

M3 - Article

C2 - 16912250

AN - SCOPUS:33748304287

VL - 40

SP - 1558

EP - 1571

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 9

ER -